Jean-Daniel Lelievre
Overview
Explore the profile of Jean-Daniel Lelievre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
1914
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiedemann A, Surenaud M, Hubert M, Lopez Zaragoza J, Ribeiro A, Rodrigues C, et al.
J Immunol
. 2025 Mar;
214(2):211-222.
PMID: 40073241
The 2022 Mpox virus (MPXV) outbreak revitalized questions about immunity against MPXV and vaccinia-based vaccines (VAC-V), but studies are limited. We analyzed immunity against MPXV in individuals infected with MPXV...
2.
Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L, et al.
EClinicalMedicine
. 2024 Dec;
77:102845.
PMID: 39649135
Background: Current HIV prophylactic vaccines evaluate HIV Env as purified proteins. CD40.HIVRI.Env is an innovative antigen delivery targeting gp140 Env from HIV Clade C 96ZM651 to CD40-expressing antigen-presenting cells, thus...
3.
Lefebvre S, Lelievre J, Rieux V, Weiss L, Ward D, Rachline A, et al.
AIDS Res Hum Retroviruses
. 2024 Oct;
41(1):20-29.
PMID: 39437018
Only one study to date has focused on people living with HIV (PLWH) who refused to participate in a HIV cure/remission-related clinical trial (HCCT)-"decliners" hereafter-that included analytical treatment interruption (ATI)....
4.
Byrne J, Gu L, Garcia-Leon A, Gaillard C, Saini G, Alalwan D, et al.
Front Immunol
. 2024 Oct;
15:1445653.
PMID: 39355249
Introduction: A clear immune correlate of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has not been defined. We explored antibody, B-cell, and T-cell responses to the third-dose...
5.
Chalouni M, Loubet P, Lhomme E, Ninove L, Barrou B, Blay J, et al.
BMC Infect Dis
. 2024 Sep;
24(1):1049.
PMID: 39333909
Background: We assessed the prognostic value of serological humoral markers measured one month after the last dose of the primary COVID-19 vaccine course for predicting the risk of severe acute...
6.
Benhamouda N, Besbes A, Bauer R, Mabrouk N, Gadouas G, Desaint C, et al.
iScience
. 2024 Aug;
27(8):110441.
PMID: 39104410
Coordinating immune responses - humoral and cellular - is vital for protection against severe Covid-19. Our study evaluates a multicytokine CD4T cell signature's predictive for post-vaccinal serological and CD8T cell...
7.
Loubet P, Lelievre J, Francois A, Botelho-Nevers E, Chidiac C, Chirio D, et al.
Int J Infect Dis
. 2024 Jun;
146:107110.
PMID: 38825164
Background: This study aimed to compare the humoral responses to mRNA COVID-19 vaccination in people living with HIV (PWH) and HIV-negative individuals. Methods: We included PWH with an undetectable viral...
8.
Alexandre M, Prague M, Lhomme E, Lelievre J, Wittkop L, Richert L, et al.
Clin Infect Dis
. 2024 May;
79(6):1447-1457.
PMID: 38819800
Background: Analytical treatment interruption (ATI) is the gold standard in HIV research for assessing the capability of new therapeutic strategies to control viremia without antiretroviral treatment (ART). The viral setpoint...
9.
Gorochov G, Ropers J, Launay O, Dorgham K, da Mata-Jardin O, Lebbah S, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e248051.
PMID: 38652471
Importance: There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response. Objective: To compare serum and salivary...
10.
Neyrinck-Leglantier D, Tamagne M, Ben Rayana R, Many S, Vingert P, LeGagneux J, et al.
Front Immunol
. 2024 Mar;
15:1354065.
PMID: 38500878
Introduction: People living with HIV (PLWH) now benefit from combined antiviral treatments that durably control viral replication. These antiretroviral treatments decrease mortality and improve quality of life in PLWH, but...